|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.01 / 0.05|
YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the Northern District of California, that a hearing will be held on December...
Affymax, Inc. (OTCQB:AFFY) today reported financial results for the second quarter ending June 30, 2014.
Affymax, Inc. (AFFY), a biopharmaceutical company, today announced that its Board of Directors has approved the liquidation and dissolution of the company, subject to stockholder approval, and plans to distribute all...
Affymax, Inc. and Takeda Pharmaceutical Company Limited (Takeda) Osaka, Japan (June 16, 2014) announced today that their Omontys ® (peginesatide) product collaboration and license agreement will terminate...
These stocks look primed to break out and trade higher from current levels.
Investors considering a purchase of Affymax Inc stock, but tentative about paying the going market price of $1.35/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2014 put at the $1 strike, which has a bid at the time of this writing of 30 cents.
Here's a look at how some of the most active names on the market today are trading technically.
Chris Lau, Kapitall:Â If there was a recent mild sell-offs in the stock market, investors would not really notice it. Wide [...]
These heavily traded stocks could have some sort of a technical or fundamental catalyst driving investors' attention.
Affymax, Inc. (Nasdaq: AFFY) today announced that it will reduce its workforce as part of a plan to focus the company’s resources on the ongoing investigation of reported hypersensitivity reactions in patients ...
Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
Deans & Lyons LLP securities lawyers announced potential claims on behalf of shareholders of Affymax (NASDAQ: AFFY) who purchased or acquired stock from December 8, 2011 until February 22, 2013.
These stocks are poised to break out and trade higher from current levels.
These stocks look poised to break out and trade higher from current levels.
A class action lawsuit has been filed on behalf of investors who purchased common stock of Affymax, Inc.
The law firm Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Affymax, Inc.
TheStreet Ratings group would like to highlight 3 stocks pushing the drugs industry lower today, Feb. 25, 2013.
Affymax, Inc. (Nasdaq: AFFY) will host a teleconference and webcast at 5:30 a.
Drug companies Affymax and Takeda issue a recall of their anemia drug Omontys after reports of severe allergic reactions in some kidney dialysis patients.
Affymax, Inc. (Nasdaq: AFFY) and Takeda Pharmaceutical Company Limited (Takeda) today have decided to voluntarily recall all lots of OMONTYS ® (peginesatide) Injection to the user level as a result of new ...
The dip-buyers have brushed off the Europe slowdown -- and bears are getting squeezed once again.
Affymax, Inc. (Nasdaq: AFFY) today announced that John Orwin, the company's chief executive officer, will present at the 15 th Annual BIO CEO & Investor Conference on Tuesday, February 12, 2013 at 9:30 a.
Affymax, Inc. (Nasdaq: AFFY) today announced the promotion of Christine Conroy, Pharm.
Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceuticals U.
Takeda Pharmaceuticals U.S.
Affymax, Inc. (Nasdaq: AFFY) today announced that John Orwin, the company's chief executive officer, will present at the 31 st Annual J.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.